Dyne Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dyne Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q4 2024.
  • Dyne Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$97.1M, a 43.5% decline year-over-year.
  • Dyne Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$344M, a 42% decline year-over-year.
  • Dyne Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$344M, a 42% decline from 2023.
  • Dyne Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$242M, a 41.6% decline from 2022.
  • Dyne Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$171M, a 14% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.